Guidelines of the Spanish Society of Cardiology in acute myocardial infarction;Guias de actuacion clinica de la Sociedad Espanola de Cardiologia en el infarto agudo de miocardio

Revista Espanola de Cardiologia

Volumn 52, Issue 11, 1999, Pages 919-956

  Arós, Fernando ^b   Loma Osorio, Ángel ^b   Alonso, Ángeles ^b   Alonso, Joaquín J ^b   Cabadés, Adolfo ^b   Coma Canella, Isabel ^b   García Castrillo, Luis ^b   García, Eulogio ^b   López de Sá, Esteban ^b   Pabón, Pedro ^b   San José, José M ^b   Vera, Antonio ^b   Worner, Fernando ^b  

^a HOSPITAL TXAGORRITXU   (Spain)

^b NONE

Author keywords

Coronary angioplasty; Coronary care unit; General ward; Myocardial infarction; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; MAGNESIUM; NITRATE; TRIFLUSAL;

ACUTE HEART INFARCTION; CORONARY CARE UNIT; HEALTH CARE ORGANIZATION; HUMAN; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; SPAIN; ST SEGMENT ELEVATION; THORAX PAIN; TREATMENT PLANNING; CARDIOLOGY; CLASSIFICATION; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HEART INFARCTION; METHODOLOGY; PATIENT CARE PLANNING; RISK FACTOR;

CARDIOLOGY; CORONARY DISEASE; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; PATIENT CARE PLANNING; RISK FACTORS; SPAIN; THROMBOLYTIC THERAPY;

EID: 0033218065     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(99)75024-4     Document Type: Review

References (198)

1. Fernández Ortiz A. Fisiopatología de la angina inestable. Papel de la rotura y trombosis de la placa aterosclerótica. Rev Esp Cardiol 1999; 52 (Supl 1): 13-23.
2. Arós F, Loma-Osorio A. Diagnóstico de la angina inestable en el servicio de urgencias. Valor y limitaciones de la clínica, el electrocardiograma y las pruebas complementarias. Rev Esp Cardiol 1999; 52 (Supl 1): 39-45.
3. Chambless L, Keil U, Dobson A, Mahonen M, Kuulasmaa K, Rajakangas AM et al. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in Cardiovascular Disease. Circulation 1997; 96: 3.849-3.859.
4. The pre-hospital management of acute heart attacks. Recommendations of a task force of the European Society of Cardiology and the European Resuscitation Council. Eur Heart J 1998; 19: 1.140.
5. Norris RM. Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. Br Med J 1998; 316: 1.065-1.070.
6. De Luna AB, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhytmia on the basis of 157 cases Am Heart J 1989; 117: 151-159.
7. O'Doherty M, Tayler DI, Quinn E, Vincent R, Chamberlain DA. Five hundred patients with myocardial infarction monitored within one hour of symptoms. Br Med J (Clin Res Ed) 1983; 286: 1.405-1.408.
8. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM et al. ACC/AHA Guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996; 28: 1.328-1.428.
9. Newby LK, Rutsch WR, Califf RM, Simoons ML, Aylward PE, Armstrong PW et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996; 27: 1.646-1.655.
10. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-775.
11. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994; 343: 311-322.
12. The Global Use of Strategies to Open Occluded coronary arteries on acute coronary syndromes (GUSTO IIB). Angioplasty substudy investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1.621-1.628.
13. Sharkey SW, Berger CR, Brunette DD, Henry TD. Impact of the electrocardiogram on the delivery of thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1994; 73: 550-553.
14. García E, Elízaga J, Pérez-Castellano N, Serrano JA, Abeytua M et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol 1999; 33: 605-611.
15. Arntz HR, Stern R, Linderer T, Schroder R. Efficiency of a physician-operated mobile intensive care unit for prehospital thrombolysis in acute myocardial infarction. Am J Cardiol 1992; 70: 417-420.
16. The European Myocardial Infarction Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 383-389.
17. Grijseels EW, Bouten MJ, Lenderink T, Deckers JW, Hoes AW, Hartman JA et al. Pre-hospital thrombolytic therapy with either alteplase or streptokinase. Practical applications, complications and long-term results in 529 patients. Eur Heart J 1995; 16: 1.833-1.838.
18. Castiella J, Valdearcos S, Alquezar ML. Análisis de las causas que motivan una excesiva demora prehospitalaria en pacientes con infarto agudo de miocardio en la provincia de Teruel. Rev Esp Cardiol 1997; 50: 860-869.
19. Iglesias ML, Pedro-Botet J, Hernández E, Solsona JF, Molina L, Alvarez A et al. Tratamiento fibrinolítico en el infarto agudo de miocardio: análisis de los tiempos de demora. Med Clin (Barc) 1996; 106: 281-284.
20. Gaspoz JM, Unger P-F, Urban P, Chevrolet J-C, Rutishuser W, Lovis C et al. Impact of a public campaign on pre-hospital delay in patients reporting chest pain. Heart 1996; 76: 150-155.
21. Blohm MB, Hartford M, Karlson BW, Luepker RV, Herlitz J. An evaluation of the results of media and educational campaigns designed to shorten the time taken by patients with acute myocardial infarction to decide to go to hospital. Heart 1996; 76: 430-434.
22. Dracup K, Alonzo AA, Atkins JM, Bennett NM, Braslow A, Clark LT et al. The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Working Group on Educational Strategies To Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. Ann Intern Med 1997; 126: 645-651.
23. Birkhead JS. Time delays in provision of thrombolytic treatment in six district hospitals. Joint Audit Committee of the British Cardiac Society and a Cardiology Committee of Royal College of Physicians of London. Br Med J 1992; 305: 445-448.
24. Eppler E, Eisenberg MS, Schaeffer S, Meischke H, Larson MP. 911 and emergency department use for chest pain: results of a media campaign. Ann Emerg Med 1994; 24: 202-208.
25. Pane GA, Salness KA. A survey of participants in a mass CPR training course. Ann Emerg Med 1987; 16: 1.112-1.116.
26. Pepe PE, Matlox KL, Duke JH, Fisher PB, Prentice FD. Effect of full-time, specialized physician supervision on the success of a large, urban emergency medical services system. Crit Care Med 1993; 21: 1.279-1.286.
27. Gulley LL, Henwood DK, Clark JJ, Eisenberg MS, Horton C. Increasing the efficiency of emergency medical services by using criteria based dispatch. Ann Emerg Med 1994; 24: 867-872.
28. Van der Hoeven JG, Waanders H, Compier EA, Van der Weyden PK, Meinders AE. Evaluation of an emergency medical system. The prognosis in patients with an out of hospital cardiac-arrest. Acta Clin Belg 1994; 44: 511.
29. Riediger G, Fleischmann-Sperber T. Efficiency and cost-effectiveness of advanced EMS in West Germany. Am J Emerg Med 1990; 8: 76-80.
30. Canto JG, Rogers WJ, Bowlby LJ, French WJ, Pearce DJ, Weaver WD. The prehospital electrocardiogram in acute myocardial infarction: is its full potential being realized? National Registry of Myocardial Infarction 2 Investigators. J Am Coll Cardiol 1997; 29: 498-505.
31. Gray AJ, Redmond AD, Martin MA. Use of the automatic external defibrillater-pacemaker by ambulance personnel: the Stockport experience. Br Med J 1987; 294: 1.133-1.135.
32. Wright D, James C, Marsden AK, Mackintosh AF. Defibrillation by ambulance staff who have had extended training. Br Med J 1989; 299: 96-97.
33. Prasad N, Wright A, Hogg KJ, Dunn FG. Direct admission to the coronary care unit by the ambulance service for patients with suspected myocardial infarction [see comments]. Heart 1997; 78: 462-464.
34. Becker LB, Pepe PE. Ensuring the effectiveness of community-wide emergency cardiac care. Ann Emerg Med 1993; 22: 354-365.
35. Kereiakes DJ, Weaver WD, Anderson JL, Feldman T, Gibler B, Aufderheide T et al. Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities. Report from the Pre-hospital Study Group and the Cincinnati Heart Project. Am Heart J 1990; 120: 773-780.
36. Aguayo de Hoyos E, Reina Toral A, Colmenero Ruiz M, Barranco Ruiz M, Pola Gallego de Guzmán MD, Jiménez Quintana MM y Grupo ARIAM. Análisis de los retrasos en el tratamiento del síndrome coconario agudo. Datos del registro ARIAM. Med Intensiva 1999; 23 280-287.
37. Torrado González E, Férriz Martín JA, Vera Almazán A, Álvarez Bueno M, Rodríguez García JJ, González Rodríguez-Villasonte P et al. Tratamiento trombolítico del infarto agudo de miocardio en el área de urgencias. Rev Esp Cardiol 1997; 50: 689-695.
38. Braun O. EMS system performance: the use of cardiac arrest timelines [see comments]. Ann Emerg Med 1993; 22: 52-61.
39. Idris HA, Becker BL, Ornato PJ, Hedges JR, Bircher NG, Chadra NC et al. Utstein-Style Guidelines for uniform reporting of laboratory CPR Research. Circulation 1996; 94: 2.324-2.336.
40. Dixon RA, Edwars IR, Pilcher J. Diazepam in immediate post-myocardial infarction period: a double blind trial. Br Heart J 1980; 43: 535-540.
41. Porth CJ, Bamrah VS, Tristani FE. The Valsalva maneuver: mechanism and clinical implications. Heart Lung 1984; 13: 507-518.
42. Antman EM. General hospital management En: Julian D, Braunwald E, editores. Management of acute myocardial infarction. Londres: W.B Saunders Company, 1994; 42-44.
43. Arós F, Loma-Osorio A. La terapia con glucosa-insulina-potasio reduce las complicaciones en la fase aguda del infarto agudo de miocardio. Argumentos en contra. Rev Esp Cardiol 1998; 51: 727-731.
44. McMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effect of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized controlled trials. JAMA 1988; 260: 1.910-1.916.
45. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
46. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
47. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 330: 753-770.
48. The International Study Group. In-hospital mortality and climical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-75.
49. The GUSTO Investigators. An International randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
50. LATE Study Group. Late assessment of thombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-766.
51. EMERAS (Estudio Multicéntrico Estreptocinasa Repúblicas de América del Sur) Collabotative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342: 767-772.
52. Yusuf S, Phil D, Sleight P, Hedd P, McMahon S. Routine Medical Management of Acute Miocardial Infarction: Lessons from overviews of recent randomised controlled trials. Circulation 1990; 82 (Supl 2): 117-134.
53. Mann E, Pajarón A, Sanz G, López-Bescós L. Trombólisis en cardiología. En: Asín E, Cosín J. Del Río A, editores. Normas de actuación clínica en cardiología. Madrid: Sociedad Española de Cardiología, 1996; 155-163.
54. Bosch X, Fernández F, Bermejo J, Curós A, Valentín V. Tratamiento del infarto agudo de miocardio no complicado. Rev Esp Cardiol 1994; 47 (Supl 1): 9-26.
55. The Global Use of Strategies To Open Occluded Coronary Artery. GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1.118-1.123.
56. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. Eur Heart J 1996; 17: 43-63.
57. Bono D, Simoons ML, Tijssen J. Effects of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122-128.
58. Bosch X, García Moll M, López-Bescós L, Pabón P, Fiol M, Ceniceros I et al. Utilización de trombolíticos en España: el estudio PRIAMHO. Rev Esp Cardiol 1996; 49 (Supl 3): 40.
59. Cabadés A, Marrugat J, Pavesi M, Loma A, Torrado E, Mancisidor X. Tiempo hasta la trombolisis en el IAM: el estudio PRIAMHO. Rev Esp Cardiol 1996; 49 (Supl 3): 40.
60. Arnold AE, Simoons ML, Detry JM. Prediction of mortality following hospital discharge after thrombolysis for acute myocardial infarction: is there a need for coronary angiography? Eur Heart J 1993; 14: 306-315.
61. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe JH et al. A comparison of inmediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328: 673-678.
62. Zijlstra F, De Boer MJ, Hoorntje JC, Reifferts S, Reiber JH, Sruyapranta H. A comparison of inmediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680-684.
63. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, García E et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278: 2.093-2.098.
64. Topol EJ. Comprehensive cardiovascular medicine. Filadelfia: Lippincott-Raven Publishers, 1998: 447.
65. Ellis SG, Ribeiro da Silva E, Heyndrickx G, Talley JD, Cernigliaro C, Steg G et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute myocardial infarction. Circulation 1994; 90: 2.280-2.284.
66. Cruz JM. Managing acute myocardial infarction: clinical implications of the TIM study. Eur Heart J 1999; 1 (Supl F):
67. Balsano F, Rizzon P, Violi F, and the STAI group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter trial. Circulation 1990; 82: 17-26.
68. CAPRIE Steering committe. A randomized blinded of clopidogrel versus aspirine in patients at risk of ischaemics events. Lancet 1996; 348: 1.329-1.339.
69. 1SIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 2: 57-66.
70. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction: patient population. Am J Cardiol 1985; 56: 1G-57G.
71. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC et al. for TIMI Investigators. Immediate versus deferred beta blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of TIMI II-B Study. Circulation 1991; 83: 422-437.
72. Pfisterer M, Cox JL, Cranger CB, Brener SJ, Naylor CD, Califf RM, Van de Wer F et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardical infarction: the GUSTO experience. J Am Coll Cardiol 1998; 32: 634-640.
73. Yusuf S, Collins R, McMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of randomised trials. Lancet 1988; I: 1.088-1.092.
74. ISIS-4 (Fourth International Study on Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium in 58,000 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
75. Gruppo Italiano per lo Studio de Ila Sopravivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal nitrate single and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1.115-1.122.
76. The AIRE Study Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
77. Kober L, Torp-Pedersen C, Carlsen JR, Bagger H, Eliasen P, Lynborg K et al. A clinical trial of the angiotensin-converting-enzyme-inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1.670-1.676.
78. Lindsay HSJ, Zaman AJ, Cowan JC. ACE inhibitors after myocardial infarction: patient selection or treatment for all? Br Heart J 1995; 73: 470-474.
79. Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. Br Med J 1991; 303: 1.499-1.503.
80. Lee KL, Woodlief LH, Topol EJ, Weaver D, Betriú A, Col J et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41,021 patients. Circulation 1995; 91: 1.659-1.668.
81. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. J Am Coll Cardiol 1990; 16: 249-292.
82. Bosch X, Echanove I. San José JM, Cabadés A. Asistencia al paciente con Infarto Agudo de Miocardio. En: Asín Cardiel E, Cosín Aguilar J. Del Río J, editores. Normas de actuación clínica en Cardiología. Madrid: Sociedad Española de Cardiología, 1996: 132-149.
83. Alegría E, López-Bescós L, Cabadés A, San José JM. Normas de actuación en el paciente con infarto agudo de miocardio. Rev Esp Cardiol 1994; 47 (supl 1): 72-76.
84. Marcus FI, Friday K, McCans J, Monn T, Hahan H, Cobb L et al. Age-related prognosis after acute myocardial infarction (the Multicenter Diltiazem Postinfarction Trial). Am J Cardiol 1990; 65: 559-566.
85. Bueno H, Vidán T, Almazán A, López Sendón JL, Delcán JL. Influence of sex on the short-term outcome of elderly patients with a first acute myocardial infarction. Circulation 1995; 92: 1.133-1.140.
86. Debusk RF, Kraemer HC, Nash E. Stepwise risk stratification soon after acute myocardial infarction. Am J Cardiol 1983; 52: 1.161-1.170.
87. Benhorin J, Moss AJ, Oakes D, and The Multicenter Diltiazem Postinfarction Trial Research Group. Prognostic significance of nonfatal myocardial reinfarction. J Am Coll Cardiol 1990; 15: 253-258.
88. DeBusk RF, and the Health and Public Policy Committee of the Clinical Efficacy Assesment Subcommitte. American College of Physicians: Evaluation of patients after recent acute myocardial infarction. Ann Intern Med 1989; 110: 485-488.
89. Azpitarte J, Navarrete A, Sánchez Ramos J. Es realmente útil la prueba de esfuerzo realizada después de un infarto de miocardio para mejorar el pronóstico de los pacientes? Arguments a favor. Rev Esp Cardiol 1998; 51: 533-540.
90. Hands ME, Lloyd BL, Robinson JS, De Klerk N, Thompson P. Prognostic significance of electrocardiographic site of infarction after correction for enzymatic size of infarction. Circulation 1986; 73: 885-891.
91. Peterson EG, Hathaway WR, Zabel KM, Woodlief C, Granger G, Topol E et al. The prognostic importance of anterior ST-depression in inferior myocardial infarctions: Results in 16, 185 patients. J Am Coll Cardiol 1995; 25: 342A.
92. Berger PB, Ryan TJ. Inferior myocardial infarction: High-risk subgroups. Circulation 1990; 81: 401-411.
93. Non-Q-Wave myocardial infarction. En: Fuster V, Ross R, Topol E, editores. Atherosclerosis and Coronary Artery Disease, Filadelfia: Lippincott-Raven, 1996; 1.097-1.124.
94. Mavric Z, Zaputovic L, Matana A, Kucic J, Rojo J, Marinovic D et al. Prognostic significance of complete atrioventricular block in patients with acute inferior myocardial infarction with and without right ventricular involvement. Am Heart J 1990; 119: 823-828.
95. Goldberg RJ, Seeley D, Becker RC, Brady P, Chen Z, Osganian V et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: A community-wide perspective. Am Heart J 1990; 119: 996-1.001.
96. García Díaz F, Vázquez García R, López-Cuerco J, Díaz Ortuño F. Valoración pronóstica de pacientes postinfarto mediante ecocardiografía bidimensional, los potenciales tardíos ventriculares y la sensibilidad barorrefleja. Rev Esp Cardiol 1998; 51: 27-34.
97. Tzivoni D, Gavish A, Zin D, Gottlieb S, Moriel M, Keren A et al. Prognostic significance of ischemic episodes in patients with previous myocardial infarction. Am J Cardiol 1988; 62: 661-664.
98. Bosch X, Théroux P, Walters D, Pelletier G, Roy D. Early postinfarction ischemia: clinical, angiographic and prognostic significance. Circulation 1987; 75: 988-995.
99. Candell-Riera J, Permanyer-Miralda G, Castel J, Rius-Davi A, Domingo E, Álvarez-Auñón E et al. Uncomplicated first myocardial infarction: strategy for comprehensive prognostic studies. J Am Coll Cardiol 1991; 18: 1.207-1.219.
100. Bosch X. Desde la torre de marfil a las trincheras. La precocidad Ilega a la unidad coronaria [comentario editorial]. Rev Esp Cardiol 1998; 51: 199-203.
101. Sanz G, Betriu A, Oller G, Matas M, Magriñá J, Paré C et al. Feasibility of early discharge after acute Q wave myocardial infarction in patients not receiving thombolytic treatment. J Am Coll Cardiol 1993; 22: 1.795-1.801.
102. Bermejo J, Muñoz JC, de la Fuente L, Álvarez A, Rubio J, Gimeno F et al Implicaciones pronósticas del alta precoz de la unidad coronaria en pacientes con infarto agudo de miocardio. Rev Esp Cardiol 1998; 51: 192-198.
103. Newby LK, Califf RM, Guerci A, Weaver WD, Col J. Horgan JH et al. Early discharge in the thrmbolytic era: an analysis of criteria for uncomplicated infarction from Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. J Am Coll Cardiol 1996; 27: 625-632.
104. Killip T, Kimball TJ. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-464.
105. Forrester JS, Diamond G, Chatterjee K, Swan HJ. Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med 1976; 295: 1.356-1.362.
106. Hibbard MD, Holmes DR, Bailey KR, Reeder GS, Bresnahan JF, Gersh BJ. Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. J Am Coll Cardiol 1992; 19: 639-646.
107. Seydoux Goy JJ, Beuret P, Stuffer JC, Vogt P, Schaller MD et al. Effectiveness of percutaneous transluminal coronary angioplasty in cardiogenic shock during acute myocardial infarction. Am J Cardiol 1992; 69: 968-969.
108. Bengston JR, Kaplan AJ, Pieper KS, Wildermann NM, Mark DB, Pryor DB et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 1992; 20: 1.482-1.489.
109. Hochman JS, Boland J, Sleeper LA, Porway M, Brinker J, Col J et al. Current spectrum of cardiogenic shock and effect on early revascularization on mortality: results of an international registry. SHOCK Registry Investigators. Circulation 1995; 91: 873-881.
110. Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med 1994; 330: 1.724-1.730.
111. Jugdutt BI, Warnica JW. Intravenous nitroglycerine therapy to limit myocardial infarct size, expansion and complications: effect of timing, dosage, and infarct location. Circulation 1988; 78: 906-919.
112. Zehender M, Kasper W, Kauder E, Schönthaler M, Geibbel A, Olschewski M et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 1993; 328: 981-988.
113. Bueno H, López-Palop R, Pérez-David E, García-García J, López-Sendón JL, Delcán JL. Combined effect of age and right ventricular involvement on acute inferior myocardial infarction prognosis. Circulation 1998; 98: 1.714-1.720.
114. Ferguson JJ, Diver DJ, Boldt M, Pasternak RC. Significance of nitroglycerine-induced hypotension with inferior wall acute myocardial infarction. Am J Cardiol 1989; 64: 311-314.
115. Goldstein JA, Barzilai B, Rosamond TL, Eisenberg PR, Jaffe AS. Determinants of hemodynamic compromise with severe right ventricular infarction. Circulation 1990; 82: 359-368.
116. Braat SH, De Zwaan C, Brugada P, Coenegracht JM, Wellens HJ. Right ventricular involvement with acute inferior wall myocardial infarction indentifies high risk of developing atrioventricular nodal conduction disturbances. Am Heart J 1984; 108: 5-13.
117. Robalino BD, Withlow PL, Underwood DA, Salcedo EE. Electrocardiographic manifestations of right ventricular infarction. Am Heart J 1989; 118: 138-144.
118. Cohn JN, Guiha NH, Broder MI, Limas CJ. Right ventricular infarction: clinical and hemodynamic features. Am J Cardiol 1974; 33: 209-214.
119. Goldstein JA, Vlahakes GJ, Verrier ED, Schiller NB, Botvinick E, Tyberg JV et al. Volume loading improves low cardiac output in experimental right ventricular infarction. J Am Coll Cardiol 1983; 2: 270-278.
120. O'Rourke MF, Norris RM, Campbell TJ, Chang VP, Sammel NL. Randomized controlled trial of intraaortic balloon counter pulsation in early myocardial infarction with acute heart failure. Am J Cardiol 1981; 47: 815-820.
121. Champagnac D, Claudel JP, Chevalier P, Desseigne P, Canu G, Chuzel M et al. Primary cardiogenic shock during acute myocardial infarction: results of emergency cardiac transplantation. Eur Heart J 1993; 14: 925-929.
122. Castells E, Calbet JM, Fontanillas C, Granados J, Manito N, Miralles A et al. Ventricular circulatory assistance with the Abiomed system as a bridge to heart transplantation. Transplan Proc 1995; 27: 2.343-2.345.
123. Bolooki H. Physiology of balloon pumping. En: Bolooki H, editor. Clinical application of intra-aortic balloon pumping. Nueva York: Futura Publishing Company, Inc., 1998; 109-161.
124. Kern MJ, Aguirre FV, Tatineni S, Penick D, Serota H, Donohue T. Enhanced coronary blood flow velocity during intraaortic balloon counterpulsation in critically ill patients. J Am Coll Cardiol 1993; 21: 359-368.
125. DeWood MA, Notske RN, Hensley GR, Shields JP, O'Grady WP, Spores J et al. Intra-aortic balloon counterpulsation with and without reperfusion for myocardial infarction shock. Circulation 1980; 61: 1.105-1.112.
126. Romero C, Worner F, Ribas M, Barthe J, Quintana E, Gausí C et al. Experiencia global del balón de contrapulsación intraaórtico en la unidad coronaria. Rev Esp Cardiol 1995; 48 (Supl 6): 73.
127. Hanson EC, Levine FH, Kay HR. Control of post-infarction ventricular irritability with the intra-aortic balloon-pump. Circulation 1980; 62 (Supl 1): 130.
128. Ohman EM, Califf RM, George BS, Quigley PJ, Kereiakes DJ, Harrelson-Woodlief L et al, and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. The use of intra-aortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction: the Thrombolysis and Angioplasty in Myocardial infarction (TAMI) Study Group. Am Heart J 1991; 121: 895-901.
129. Ohman EM, George BS, White CJ, Kern MJ, Gurbel PA, Freedman RJ et al, for the randomized IABP Study Group. Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: results of a randomized trial. Circulation 1994; 90: 792-799.
130. Stone GW, Marsalese D, Brodie BR, Griffin JJ, Donohue B, Constantini C et al. A prospective, randomized evaluation of prophilactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol 1997; 29: 1.459-1.467.
131. Scholz KH, Ragab S, Von zur Mühlen F, Schröder T, Werner GS, Mindel L et al. Complications of intra-aortic balloon counterpulsation. The role of catheter size and duration of support in a multivariate analysis of risk. Eur Heart J 1998; 19: 458-465.
132. Galve E, García del Castillo H, Evangelista A, Batlle J, Permanyer G, Soler J. Pericardial effusion in the course of acute myocardial infarction: incidence, natural history, and clinical relevance. Circulation 1986; 73: 294-299.
133. Somolinos M, Violán S, Sanz R, Marrero P. Early pericarditis after acute myocardial infarction: A clinical echocardiographic study. Crit Car Med 1987; 15: 648-651.
134. Totter GH, Muller JE, Stone PH, Willich SN, Davis VG, Poole WK et al, and the MILIS Study Group. Pericarditis in acute myocardial infarction: characterization and clinical significance. Am Heart J 1989; 117: 86-92.
135. Spodick DH. Pericardial complications of myocardial infarction. En: Francis GS, Alpert JS, editores. Coronary Care. Boston: Little, Brown and Co, 1995; 333.
136. Khanderia BK, Shub C, Nishimura RA, Miller FA Jr, Seward JB, Tajik AJ. To anticoagulate or not: implications for the management of patients with acute myocardial infarction complicated by both left ventricular thrombus and pericardial effusion. Can J Cardiol 1987; 3: 173-176.
137. Berman J, Haffajee CI, Alpert JS. Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. Am Heart J 1981; 101: 750-753.
138. Shahar A, Hod H, Barabash GM, Kaplinsky E, Motro M. Disapperance of a syndrome: Dressler's syndrome in the era of thrombolysis. Cardiology 1994; 85: 255-258.
139. Uuskiula MM, Lamp KM, Martin SI. Relationship between the clinical course of acute myocardial infarction and specific sensitization of lymphocytes and lymphotoxin production. Kardiologial 1987; 26: 57.
140. Figueras J, Cinca J, Valle V, Rius J. Prognostic implications of early spontaneous angina after acute myocardial infarction. Int J Cardiol 1983; 4: 461-472.
141. Sellier P, Plat F, Corona P, Payen B, Audouin P, Ourbak P. Prognostic significance of angina pectoris recurring soon after myocardial infarction. Eur Heart J 1988; 9: 447-453.
142. Galjee MA, Visser FC, De Cock CC, Van Eenige MJ. The prognostic value, clinical, and angiographic characteristics of patients with early post-infarction angina after a first myocardial infarction. Am J Cardiol 1987; 59: 241-244.
143. Kennedy JW, Ritchi JL, Davis KB, Fritz JK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477-1482.
144. Barbagelata A, Granger CB, Topol EJ, Worley SJ, Kereiakes DJ, George BS et al, for the TAMI study group. Frequency, significance and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1995; 76: 1.007-1.013.
145. Stone GW, Brodie BR, Griffin JJ, Morice MC, Constantini C, Goar FG et al, for the primary angioplasty in myocardial infarction (PAMI) stent pilot trial investigators. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in hospital and 30-day results of the PAMI stent pilot trial. J Am Coll Cardiol 1998; 31: 23-30.
146. Pan M. Angioplastia coronaria: stent siempre en arterias de más de 2,5 mm? Argumentes a favor. Rev Esp Cardiol 1999; 52: 79-84.
147. Betriu A, Califf R, Bosch X, Guerci A, Stebbins AL, Barbagelata NA et al, for the GUSTO-I investigators: Recurrent ischemia after thrombolysis: Importance of associated clinical findings. J Am Coll Cardiol 1998; 31: 94-102.
148. Tabata H, Mizuno K, Arakawa K, Satomura K, Shibuya T, Kurita A et al. Angioscopic identification of coronary thrombus in patients with postinfarction angina. J Am Coll Cardiol 1995; 25: 1.282-1.285.
149. Braunwald E. Unstable angina: A classification. Circulation 1989; 80: 410-414.
150. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein IIb/lIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1.488-1.497.
151. Califf RM. Acute myocardial infarction. En: Smith TW, editor. Cardiovascular therapeutics. Filadelfia: WB Saunders Company, 1996.
152. Worner F, Romero C, Ribas M, Quintana E, Barthe J, Gausí C et al. Utilitat del baló de contrapulsació intraaórtica en l'angina refractària severa. Rev Soc Catalana Cardiol 1995; 1: 10.
153. Gill JB, Cairns JA, Roberts RS, Tech M, Constantini L, Sealey BJ et al. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med 1996; 334: 65-70.
154. Gottlieb SO, Gottlieb SH, Achuff SC, Baumgardner R, Mellitis ED, Weisfeld ML et al. Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients. JAMA 1988; 259: 1.030-1.035.
155. Curri P, Saltissi S. Transient myocardial ischemia after acute myocardial infarction. Br Heart J 1990; 64: 299-303.
156. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith Ch, Ellis S et al, and the TAMI study group. Consequences of reoclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82: 781.
157. Ohman EM, Armstrong PM, Guerci AD, Vahanian A. for the GUSTO trial investigators. Reinfarction after thrombolytic therapy. Experience for the GUSTO trial. Circulation 1993; 88 (Supl 1): 490.
158. Mueller HS, Forman SA, Menegus MA, Cohen LS, Knatterud GL, Braunwald E. for the TIMI investigators. Prognostic significance of nonfatal reinfarction during 3-year follow-up: Results of the thrombolysis in myocardial infarction (TIMI) phase II clinical trial. J Am Coll Cardiol 1995; 26: 900-907.
159. Purvis JA, McNeil AJ, Roberts MJD, Dalzell GW, Wilson CM, Campbell NP et al. First-year follow-up after repeat thrombolytic therapy with recombinant-tissue plasminogen activator for myocardial reinfarction. Coronary Artery Dis 1992; 3: 713-720.
160. Simoons ML, Arnout J, Van den Brand M, N_ssen K, Verstraete M, for the European cooperative study group. Retreatment with alteplase for early signs of reocclusion after thrombolysis: the European cooperative study group. Am J Cardiol 1993; 71: 524-528.
161. Chatterjee K. Complications of acute myocardial infarction. Curr Prob Cardiol 1993; 18: 1-79.
162. López-Sendón JL, González A, López de Sá E, Coma-Canella I, Roldán I, Domínguez F et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarction. Sensitivity and specificity of clinical, hemodynamic and electrocardiographic criteria. J Am Coll Cardiol 1992; 19: 1.145-1.153.
163. Behar S, Zahavi Z, Golbourt U, Reicher Reiss HL. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction: SPRINT Study Group. Eur Heart J 1992; 13: 45-50.
164. Kyriakidis M, Barbetseas J, Antonopoulus A, Skouros C, Tentoloruis C, Toutouzas P. Early atrial arrhythmias in acute myocardial infarction, role of the sinus node artery. Chest 1992; 101: 944-947.
165. Nordrehaug JE, Von der Lippe G. Hypokalaemia and ventricular fibrillation in acute myocardial infarction. Br Heart J 1983; 50: 525-529.
166. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care, part III: adult avanced cardiac life support. JAMA 1992; 268: 2.199-2.241.
167. Berger PB, Ruocco NA Jr, Ryan TJ, Frederik MM, Jacobs AK, Faxon DP. Incidence and prognostic implications of heart block complicating nferior myocardial infarction treated with thrombolytic therapy: results from TIMI-II. J Am Coll Cardiol 1992; 20: 533-540.
168. Kishon Y, Oh JK, Schaff HV, Mullany CJ, Tajik AJ, Gersh BJ. Mitral valve operation in post-infarction rupture of papillar muscle: immediate results and long-term follow-up of 22 patients. Mayo Clin Proc 1992; 67: 1.023-1.030.
169. Lemery R, Smith HC, Giuliani ER, Gersh BJ. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. Am J Cardiol 1992; 70: 147-151.
170. Figueras J, Cortadellas J, Evangelista A, Soler-Soler J. Medical management of selected patients with left ventricular free wall rupture during acute myocardial infarction. J Am Coll Cardiol 1997; 29: 512-518.
171. Guías de actuación clínica de la Sociedad Española de Cardiología en pruebas de esfuerzo. Rev Esp Cardiol. En prensa.
172. ACC/AHA Guidelines for coronary angiography: executive summary and recommendations. Circulation 1999; 17: 2.345-2.357.
173. Petersen ED, Shaw LJ, Califf RM. Risk stratification after myocardial infarction. Ann Intern Med 1997; 126: 561-582.
174. ACC/AHA Guidelines for implantation of cardiac pacemakers and antiarrhytamia devices. J Am Coll Cardiol 1998; 31: 1.175-1.209.
175. Guías de actuación clínica de la Sociedad Española de Cardiología en arritmias. Rev Esp Cardiol. En prensa.
176. Previtalli M, Festiveau R, Lanzarini L, Cavalotti C, Klersy C. Prognostic value of myocardial viability and isquemia detected by dobutamine stress echocardiography early after acute myocardial infarction treated with thrombolysis. J Am Coll Cardiol 1998; 32: 380-386.
177. Picano E, Sicari R, Landi P, and EDIC Study Group, Prognostic value of myocardial viability in medically treated patients with global left ventricular dysfunction early after an acute uncomplicated myocardial infarction. Circulation 1998; 98: 1.078-1.084.
178. Udelson JE. Steps forward in the assessment of myocardial viability in left ventricular disfunction. Circulation 1998; 97: 833-838.
179. Barrabés Riu JA, García-Dorado D, Martín JA, Coma Canella I, Valle Tudela V. Papel de las exploraciones no invasivas en el manejo de la cardiopatía isquémica, III. Estimación de la viabilidad miocárdica. Rev Esp Cardiol 1997; 50: 75-82.
180. Margonatto A, Ballarotto C, Bonetti F, Cappelletti A, Sciammarella M, Cianlone D et al. Assessment of residual tissue viability by exercise testing in recent myocardial infarction: comparison by electrocardiogram and myocardial perfusion scintigraphy. J Am Coll Cardiol 1992; 19: 948-952.
181. Cornel J, Bax J, Elhendy A, Maat APWM, Kimman GP, Geleijnse ML et al. Biphasic response to dobutamine predicts improvement of global left ventricular function after surgical revascularization in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31: 1.002-1.010.
182. Perdigao C, Ribero C. Trombos intraventriculares no enfarte agudo do miocardio. Estudo Multicentrico Iberico. Apresentacao do protocolo de estudo e de alguns resultados preliminares. Rev Port Cardiol 1991; 5: 401-410.
183. Domenicucci S, Chiarella F, Bellotti P, Bellone P, Lupi G, Vecchio C. Long-term prospective assessment of left ventricular thrombus in anterior wall acute myocardial infarction and implications for a rational approach to embolic risk. Am J Cardiol 1999; 83: 519-524.
184. Van Dantzig JM, Delemarre BJ, Bot H, Visser CA. Left ventricular thrombus in acute myocardial infarction. Eur Heart J 1996; 17: 1.640-1.645.
185. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1.434-1.503.
186. Fuster V, Pearson TA. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996; 27: 957-1047.
187. Guías de la Sociedad Española de Cardiología en prevención (factores de riesgo) y rehabilitación. Rev Esp Cardiol. En prensa.
188. Antiplatelet Trialist's Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
189. Hennekens CH, Dyken JL, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease. A statement for Healthcare Professionals from the American Heart Association. Circulation 1997; 96: 2.751-2.753.
190. Yusuf S, Peto R, Lewis J, Collins R, Fleight P. Betablockade during and after myocardial infarction, an overview of the randomised trials. Prog Cardiovasc Dis 1984; 27: 335-371.
191. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy ET et al, for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargment Trial (SAVE). N Engl J Med 1992; 327: 669-677.
192. Ambrosioni E, Borghi C, Magnami B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-85.
193. Kingma JH, Van Gilts WH, Peels CH, Dambrink JH, Verheugt FW, Wielenga RP. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction: results from the Captopril and Thrombolysis Study (CATS). Eur Heart J 1994; 15: 898-907.
194. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-687.
195. ASPECT Research Group, Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction: anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet 1994; 343: 499-503.
196. Cairns JA, Markham BA. Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction. JAMA 1995; 273: 965-967.
197. Weintraub WS, Ba'albaki HA. Decision analysis concerning the application of echocardiography to the diagnosis and treatment of mural thrombi after anterior wall acute myocardial infarction. Am J Cardiol 1989; 64: 708-716.
198. Huiley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of strogen plus progestin for secondary prevention of coronary heart disease on postmenopausal women. JAMA 1998; 280: 605-613.